• EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    • Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
    • Eur J Cancer. 2022 Dec 13 [2023 Mar];181:79-91. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.
    • Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
    • Casalino S, Bruce S, Serfas K, Altman AD, Kean S, Lambert P, McManus KJ, Hartley JN, Nachtigal MW.
    • J Genet Couns. 2023 Feb 20. doi: 10.1002/jgc4.1684. Epub ahead of print.
    • The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication.
    • Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M.
    • Curr Oncol. 2023 Feb 18;30(2):2429-2440. doi: 10.3390/curroncol30020185.
    • Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1/2 pathogenic variant carriers.
    • Isselhard A, Tüchler A, Dick J, Scherer A, Aue V, Schmutzler RK, Rhiem K.
    • Psychooncology. 2023 Feb 12. doi: 10.1002/pon.6111. Epub ahead of print.
    • Counselling of path_BRCA carriers who are considering risk-reducing oophorectomy.
    • Manley K, Ryan N, Jenner A, Newton C, Hillard T.
    • Post Reprod Health. 2023 Feb 9:20533691231156640. doi: 10.1177/20533691231156640. Epub ahead of print.
    • Review
    • Financial toxicity in BRCA1 and BRCA2 carriers.
    • Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM.
    • Gynecol Oncol. 2023 Jan 24;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub ahead of print.
    • Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected BRCA1/2 Mutation Carriers.
    • Isselhard A, Lautz Z, Töpper M, Rhiem K, Schmutzler R, Vitinius F, Fischer H, Berger-Höger B, Steckelberg A, Beifus K, Köberlein-Neu J, Stock S.
    • Int J Environ Res Public Health. 2023 Jan 17;20(3):1684. doi: 10.3390/ijerph20031684.
    • Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
    • Vanderwal A, Lewis J, Basil J, Atzinger C, Widmeyer K.
    • J Genet Couns. 2023 Jan 15. doi: 10.1002/jgc4.1674. Epub ahead of print.
    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary
    • Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.
    • Pederson HJ, Batur P.
    • Menopause. 2023 Jan 10. doi: 10.1097/GME.0000000000002136. Epub ahead of print.
    • Review
    • The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E, Cascardi E, Cormio G.
    • Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    • Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
    • Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.
    • Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model.
    • Etchegary H, Pike A, Puddester R, Watkins K, Warren M, Francis V, Woods M, Green J, Savas S, Seal M, Gao Z, Avery S, Curtis F, McGrath J, MacDonald D, Burry TN, Dawson L.
    • PLoS One. 2022 Dec 22;17(12):e0279317. doi: 10.1371/journal.pone.0279317.
    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study.
    • Dick J, Tüchler A, Brédart A, Vitinius F, Wassermann K, Rhiem K, Schmutzler RK.
    • Hered Cancer Clin Pract. 2022 Dec 19;20(1):38. doi: 10.1186/s13053-022-00244-y.
    • Informational needs of individuals from BRCA-harboring families: a systematic review and content analysis.
    • Park SY, Kim Y, Kim S, Katapodi MC.
    • Genet Med. 2022 Dec 18:S1098-3600(22)01068-1. doi: 10.1016/j.gim.2022.100001. Epub ahead of print.
    • Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
    • Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R.
    • Cancers (Basel). 2022 Dec 12;14(24):6117. doi: 10.3390/cancers14246117.
    • Providers' perspectives on the reproductive decision-making of BRCA-positive women.
    • Dason ES, Drost L, Greenblatt EM, Scheer AS, Han J, Sobel M, Allen L, Jacobson M, Doshi T, Wolff E, McMahon E, Jones CA.
    • BMC Womens Health. 2022 Dec 8;22(1):506. doi: 10.1186/s12905-022-02093-2.
    • BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
    • Sun J, Chu F, Pan J, Zhang Y, Yao L, Chen J, Hu L, Zhang J, Xu Y, Wang X, Cao W, Xie Y.
    • J Clin Oncol. 2022 Dec 8:JCO2200833. doi: 10.1200/JCO.22.00833. Epub ahead of print.
    • Nest Genomics Building EHR-Integrated Clinical Decision Support for Genetics-Informed Care.
    • Cohen JK.
    • GenomeWeb. Disease Areas. Cancer. 2022 Oct 25.
    • PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    • Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubinski J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK.
    • Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3.
    • Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City.
    • Lima SM, Nazareth M, Schmitt KM, Reyes A, Fleck E, Schwartz GK, Terry MB, Hillyer GC.
    • J Community Genet. 2022 Oct 13. doi: 10.1007/s12687-022-00610-2. Epub ahead of print.
    • Population genomic screening: Ethical considerations to guide age at implementation.
    • Spencer SJ, Fullerton SM.
    • Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.
    • Why I Chose Preventive Mastectomy.
    • Swirsky N.
    • FORCE. Blog. 2022 Oct 3.
    • Satisfaction après mastectomie de réduction de risque associée à une reconstruction chez les patiente porteuses d’une mutation génétique [Satisfaction after risk reducing mastectomy related to breast reconstruction surgery in patient with hereditary genetic mutation].
    • Manivit C, Dannepond A, Brun JL, Pinsolle V, Casoli V, Charitansky H, Babin-Commeny J.
    • Gynecol Obstet Fertil Senol. 2022 Oct;50(10):650-656. French. doi: 10.1016/j.gofs.2022.06.007. Epub 2022 Jun 28.
    • [Article in French]
    • Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    • Comeaux JG, Culver JO, Lee JE, Dondanville D, McArthur HL, Quinn E, Gorman N, Ricker C, Li M, Lerman C.
    • Mol Genet Genomic Med. 2022 Oct;10(10):e2031. doi: 10.1002/mgg3.2031. Epub 2022 Aug 25.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Getting Past the Shock of a Previvor Diagnosis and Making a Plan.
    • Swirsky N.
    • FORCE. Blog. 2022 Sep 21.
    • Optimal breast cancer risk reduction policies tailored to personal risk level.
    • Ergun MA, Hajjar A, Alagoz O, Rampurwala M.
    • Health Care Manag Sci. 2022 Sep;25(3):363-388. doi: 10.1007/s10729-022-09596-2. Epub 2022 Jun 10.
    • Breast cancer genetic mutation: Synthesis of women's experience.
    • McNamara N, Feeney M, Giltenane M, Dowling M.
    • J Clin Nurs. 2022 Aug 25. doi: 10.1111/jocn.16498. Epub ahead of print.
    • Review
    • High Risk Breast Cancer Screening is a Double Edged Sword: A Qualitative Study of Patient Perspectives on the Ontario High Risk Breast Cancer Screening Program.
    • Deng SX, Castelo M, Reel E, Naganathan G, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Clin Breast Cancer. 2022 Aug 19:S1526-8209(22)00183-5. doi: 10.1016/j.clbc.2022.08.004. Epub ahead of print.
    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • BRCA mutation carriers' perception about benefits and risks associated with combined hormonal contraceptives use.
    • Grandi G, Monari F, Boggio Sola V, Cortesi L, Toss A, Del Savio MC, Melotti C, Centurioni MG, Gustavino C, Varesco L, Facchinetti F, Barra F.
    • Eur J Contracept Reprod Health Care. 2022 Aug 10:1-6. doi: 10.1080/13625187.2022.2107199. Epub ahead of print.
    • A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".
    • Warner NZ, Groarke A.
    • BMC Health Serv Res. 2022 Aug 6;22(1):1007. doi: 10.1186/s12913-022-08372-w.
    • What are the considerations in patient selection and timing of risk-reducing mastectomy?
    • Pederson HJ, Kurian AW, Al Hilli Z.
    • Cleve Clin J Med. 2022 Aug 1;89(8):442-444. doi: 10.3949/ccjm.89a.21114.
    • Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
    • Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML.
    • Ann Surg Oncol. 2022 Aug;29(8):4706-4713. doi: 10.1245/s10434-022-11756-1. Epub 2022 May 18.

    Related:

    Commentary:

    A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.

    ASO Visual Abstract: Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery and Those Treated With Mastectomy. (Annals of Surgical Oncology)

    • Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study.
    • French DP, McWilliams L, Howell A, Evans DG.
    • Breast. 2022 Aug;64:47-49. doi: 10.1016/j.breast.2022.05.001. Epub 2022 May 9.
    • Surveillance mammography after treatment for male breast cancer.
    • Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ.
    • Breast Cancer Res Treat. 2022 Aug;194(3):693-698. doi: 10.1007/s10549-022-06645-w. Epub 2022 Jun 17.
    • Further validation of the Perceptions of Uncertainties in Genome Sequencing scale among patients with cancer undergoing tumor sequencing.
    • Umstead KL, Campbell R, Napier CE, Bartley N, Best MC, Butow PN, Biesecker BB.
    • Clin Genet. 2022 Aug;102(2):110-116. doi: 10.1111/cge.14169. Epub 2022 Jun 10.
    • Decision thresholds with genetic testing.
    • Felder S.
    • Eur J Health Econ. 2022 Aug;23(6):1071-1078. doi: 10.1007/s10198-021-01410-0. Epub 2021 Dec 2.
    • Risk-reducing Salpingo-oophorectomy consults and practices during the COVID-19 pandemic.
    • O'Mara AE, Benedict C, Kurian AW, Wagner SK, Diver E.
    • Gynecol Oncol Rep. 2022 Aug;42:101036. doi: 10.1016/j.gore.2022.101036. Epub 2022 Jun 28.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • Study: Risk-reducing ovarian cancer surgery and quality of life.
    • [No author given]
    • FORCE. XRAY. 2022 Jul 26.

    Related:

    Original research:

    Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

    • Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.
    • Lourenção M, Simões Correa Galendi J, Galvão HCR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, de Oliveira JHC, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jul 11;12:951310. doi: 10.3389/fonc.2022.951310.
    • Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes.
    • Burnell M, Gaba F, Sobocan M, Desai R, Sanderson S, Loggenberg K, Gessler S, Side L, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 Jul 4. doi: 10.1111/1471-0528.17253. Epub ahead of print.
    • Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
    • Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.
    • Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.
    • BRCA1/2 pathogenetic variant carriers and reproductive decisions: Gender differences and factors associated with the choice of preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND).
    • Lombardi L, Trumello C, Stuppia L, Antonucci I, Brandão T, Babore A.
    • J Assist Reprod Genet. 2022 Jul;39(7):1433-1443. doi: 10.1007/s10815-022-02523-y. Epub 2022 Jun 4.
    • Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.
    • Adolph L, Warias A, Stairs J, Collins-McNeil K, Penney L, Kieser K.
    • BMC Womens Health. 2022 Jun 29;22(1):263. doi: 10.1186/s12905-022-01844-5.
    • Helping Patients Understand and Cope with BRCA Mutations.
    • Makhnoon S, Arun B, Bedrosian I.
    • Curr Oncol Rep. 2022 Jun;24(6):733-740. doi: 10.1007/s11912-022-01254-8. Epub 2022 Mar 18.
    • Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 May 2 [eCollection 2022 Jun];41:100989. doi: 10.1016/j.gore.2022.100989.
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations.
    • Sawhney MS, Calderwood AH, Thosani NC, Rebbeck TR, Wani S, Canto MI, Fishman DS, Golan T, Hidalgo M, Kwon RS, Riegert-Johnson DL, Sahani DV, Stoffel EM, Vollmer CM Jr, Qumseya BJ; Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE.
    • Gastrointest Endosc. 2022 May;95(5):817-826. doi: 10.1016/j.gie.2021.12.001. Epub 2022 Feb 16.

    Related:

    Guideline:

    American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence.

    Video: 2022 May Author Interview-Bashar Qumseya, Mandeep S. Sawhney, and Audrey H. Calderwood. (Author Interview Series / YouTube)

    News: ASGE Expands BRCA Screening for Pancreatic Cancer. (Inside Precision Medicine)

    • Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.
    • Elhanan G, Kiser D, Neveux I, Dabe S, Bolze A, Metcalf WJ, Lu JT, Grzymski JJ.
    • Front Genet. 2022 Apr 27;13:866169. doi: 10.3389/fgene.2022.866169.
    • “You are BRCA2-Positive”: Studies that Have Helped Me.
    • Dreher ME.
    • FORCE. Blog. 2022 Apr 5.
    • Information needs of women undergoing gynaecological risk reduction surgery: Applying patient-reported findings to improve service delivery.
    • Jennings B, Ramis MA, Kynoch K, Jagasia N.
    • Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):286-293. doi: 10.1111/ajo.13456. Epub 2021 Nov 9.
    • Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.
    • Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, Boccia S, Dabrock P, Emons G, Gaissmaier W, Gronwald J, Houwaart S, Huster S, Kast K, Katalinic A, Linn SC, Moorthie S, Pharoah P, Rhiem K, Spranger T, Stoppa-Lyonnet D, van Delden JJM, van den Bulcke M, Woopen C.
    • Breast Care (Basel). 2022 Apr;17(2):208-223. doi: 10.1159/000517182. Epub 2021 Aug 12.
    • Outcomes of support groups for carriers of BRCA 1/2 pathogenic variants and their relatives: a systematic review.
    • Bertonazzi B, Turchetti D, Godino L.
    • Eur J Hum Genet. 2022 Apr;30(4):398-405. doi: 10.1038/s41431-022-01044-7.
    • "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.
    • Reyes KG, Clark C, Gerhart M, Newson AJ, Ormond KE.
    • Fam Cancer. 2022 Apr;21(2):143-155. doi: 10.1007/s10689-021-00251-3. Epub 2021 Apr 15.
    • The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1.
    • Crook A, Kwa R, Ephraums S, Wilding M, Thiyagarajan L, Fleming J, Moore K, Berman Y.
    • Fam Cancer. 2022 Apr;21(2):241-253. doi: 10.1007/s10689-021-00259-9. Epub 2021 May 8.
    • "It was a no-brainer": A qualitative study of factors driving previvors' decision-making when considering risk-reducing salpingectomy with delayed oophorectomy.
    • Gellman C, Ezratty C, Schwarz J, Kolev V, Blank SV.
    • Gynecol Oncol Rep. 2022 Feb 26 [eCollection 2022 Apr];40:100948. doi: 10.1016/j.gore.2022.100948.
    • Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
    • Ro V, McGuinness JE, Guo B, Trivedi MS, Jones T, Chung WK, Rao R, Levinson E, Koval C, Russo D, Chilton I, Kukafka R, Crew KD.
    • JCO Oncol Pract. 2022 Apr;18(4):e472-e483. doi: 10.1200/OP.21.00322. Epub 2021 Oct 27.
    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.
    • Simões Corrêa Galendi J, Kautz-Freimuth S, Stock S, Müller D.
    • Cancers (Basel). 2022 Mar 31;14(7):1786. doi: 10.3390/cancers14071786.
    • Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    • Bilash T, Walker LM.
    • J Clin Oncol. 2022 Mar 20;40(9):1027-1029. doi: 10.1200/JCO.21.01249. Epub 2022 Jan 12.
    • Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.
    • Hesse-Biber S, Seven M, Jiang J, Schaik SV, Dwyer AA.
    • Cancers (Basel). 2022 Mar 15;14(6):1494. doi: 10.3390/cancers14061494.
    • Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    • Kautz-Freimuth S, Redaèlli M, Isselhard A, Shukri A, Vodermaier A, Rhiem K, Schmutzler R, Stock S.
    • Trials. 2022 Feb 16;23(1):157. doi: 10.1186/s13063-022-06081-7.
    • Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    • Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, Blank SV, Yemelyanova A, Magliocco AM, Finkel MA, Moore TE, Thaker PH.
    • Cancer. 2022 Feb 15;128(4):654-664. doi: 10.1002/cncr.34023. Epub 2021 Nov 17.
    • Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.
    • Padmanabhan H, Hassan NT, Wong SW, Lee YQ, Lim J, Hasan SN, Yip CH, Teo SH, Thong MK, Mohd Taib NA, Yoon SY.
    • PLoS One. 2022 Feb 15;17(2):e0263675. doi: 10.1371/journal.pone.0263675.
    • BRCA2, Early-Stage Prostate Cancer and a Decision at 54.
    • Axler J.
    • FORCE. Blog. 2022 Feb 11.
    • Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study.
    • Berger-Höger B, Vitinius F, Fischer H, Beifus K, Köberlein-Neu J, Isselhard A, Töpper M, Wiedemann R, Rhiem K, Schmutzler R, Stock S, Steckelberg A.
    • BMC Nurs. 2022 Feb 10;21(1):42. doi: 10.1186/s12912-022-00810-8.
    • Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.
    • Li J, Jia Z, Zhang M, Liu G, Xing Z, Wang X, Huang X, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Front Oncol. 2022 Jan 10;11:763161. doi: 10.3389/fonc.2021.763161.
    • Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    • Siegel A, Bremer RC, Klein WMP, Savage SA, Loud JT, Khincha PP.
    • Breast Cancer Res Treat. 2022 Jan;191(1):159-167. doi: 10.1007/s10549-021-06410-5. Epub 2021 Oct 15.
    • Factors affecting surgical decision-making in carriers of BRCA1/2 pathogenic variants undergoing risk-reducing surgery at a dedicated hereditary ovarian cancer clinic.
    • Jacobson MR, Walker M, Ene GEV, Firestone C, Bernardini MQ, Allen L, Huszti E, Sobel M.
    • Menopause. 2021 Dec 6;29(2):151-155. doi: 10.1097/GME.0000000000001900.

    Related:

    Video: Video Summary (Menopause)

    • Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.
    • Landau C, Novak AM, Ganz AB, Rolnik B, Friedman E, Lev-Ari S.
    • JAMA Netw Open. 2021 Dec 1;4(12):e2139670. doi: 10.1001/jamanetworkopen.2021.39670.
    • Underutilisation of breast cancer prevention medication in Australia.
    • Macdonald C, Chamberlain JA, Mazza D, Milne RL; kConFab investigators, Phillips KA.
    • Breast. 2021 Dec;60:35-37. doi: 10.1016/j.breast.2021.08.013. Epub 2021 Aug 23.
    • Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer.
    • Evans DG, Gandhi A, Wisely J, Clancy T, Woodward ER, Harvey J, Highton L, Murphy J, Barr L, Howell SJ, Lalloo F, Harkness EF, Howell A.
    • Breast. 2021 Dec;60:45-52. doi: 10.1016/j.breast.2021.08.015. Epub 2021 Aug 26.
    • Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior.
    • Yanes T, Meiser B, Kaur R, Young MA, Mitchell PB, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Betz-Stablein B, James PA.
    • Genet Med. 2021 Dec;23(12):2316-2323. doi: 10.1038/s41436-021-01288-6. Epub 2021 Aug 2.

    Related:

    Podcast: GenePod—November: The potential impact of a PRS-based breast cancer risk assessment. (Genetics in Medicine)

    • Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study.
    • Forbes Shepherd R, Forrest LE, Tutty E, Pearce A, Devereux L, James PA, Campbell IG, Trainer A, Young MA.
    • Genet Test Mol Biomarkers. 2021 Dec;25(12):741-748. doi: 10.1089/gtmb.2021.0115.
    • Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.
    • Mittendorf KF, Knerr S, Kauffman TL, Lindberg NM, Anderson KP, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Zepp JM, Syngal S, Wilfond BS, Goddard KAB.
    • JCO Precis Oncol. 2021 Nov 3;5:PO.21.00233. doi: 10.1200/PO.21.00233.
    • Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1/2 mutations.
    • Smith MJ, Gerber D, Olsen A, Khouri OR, Wang Y, Liu M, Smith J, Pothuri B.
    • Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.
    • November: The potential impact of a PRS-based breast cancer risk assessment.
    • Yanes T, Graber C.
    • Genetics in Medicine. GenePod. 2021 Nov.

    Related:

    Original research:

    Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior.

    • The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    • Greer AC, Lanes A, Poorvu PD, Kennedy P, Thomas AM, Partridge AH, Ginsburg ES.
    • Cancer. 2021 Oct 15;127(20):3872-3880. doi: 10.1002/cncr.33601. Epub 2021 Jun 23.
    • Fertility Considerations for Reproductive-Aged Carriers of Deleterious BRCA Mutations: A Call for Early Intervention.
    • Fine E, Knoll MA, Maslow BL.
    • JCO Oncol Pract. 2021 Oct 4:OP2100389. doi: 10.1200/OP.21.00389. Epub ahead of print.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.
    • Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani GA, Del Savio MC, Facchinetti F.
    • Psychooncology. 2021 Oct;30(10):1711-1719. doi: 10.1002/pon.5714. Epub 2021 May 28.
    • Exploring Implementation of Personal Breast Cancer Risk Assessments.
    • Sierra MA, Wheeler JCW, Devereux L, Trainer AH, Keogh L.
    • J Pers Med. 2021 Sep 30;11(10):992. doi: 10.3390/jpm11100992.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Understanding BRCA1/2 Previvors’ Information and Support Needs: Results from a Community Needs Assessment.
    • Boumis JK, Dean M.
    • FORCE. Blog. 2021 Sep 20.
    • After Three Cancer Diagnoses and a Positive BRCA Test, Endometrial Cancer.
    • Walter P.
    • FORCE. Blog. 2021 Sep 9.
    • Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups.
    • Schwartz C, Chukwudozie IB, Tejeda S, Vijayasiri G, Abraham I, Remo M, Shah HA, Rojas M, Carillo A, Moreno L, Warnecke RB, Hoskins KF.
    • JAMA Netw Open. 2021 Sep 1;4(9):e2123751. doi: 10.1001/jamanetworkopen.2021.23751.

    Related:

    Commentary:

    Practice-Changing Opportunity to Reduce Disparities in Screening Mammography-Implementation of Risk Assessment in Primary Care.

    • Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    • Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Demsky R, Mancuso T, Sun P, Narod SA.
    • Ann Surg Oncol. 2021 Sep;28(9):4967-4973. doi: 10.1245/s10434-021-09855-6. Epub 2021 Mar 24.

    Related:

    Commentary:

    Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy.

    • Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    • Steenbeek MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, van Doorn HC, Keurentjes JHM, van Beurden M, Zweemer RP, Gaarenstroom KN, Penders CGJ, Brood-van Zanten MMA, Vos MC, Piek JM, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, IntHout J, de Hullu JA, Hermens RPMG.
    • Gynecol Oncol. 2021 Aug 26:S0090-8258(21)01317-2. doi: 10.1016/j.ygyno.2021.08.019. Epub ahead of print.
    • Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    • Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • Cancer Res Treat. 2021 Aug 9. doi: 10.4143/crt.2021.449. Epub ahead of print.
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art.
    • Terribile DA, Mason EJ, Murando F, DI Leone A, Sanchez AM, Scardina L, Magno S, Franco A, D'Archi S, Natale M, Lucci Cordisco E, Masetti R, Franceschini G.
    • Minerva Surg. 2021 Aug 2. doi: 10.23736/S2724-5691.21.09009-2. Epub ahead of print.
    • Review
    • Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    • Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    • JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.

    Related:

    Identifier: NCT02321228: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA). (ClinicalTrials.gov)

    Research news: Study: Risk-reducing ovarian cancer surgery and quality of life. (FORCE. XRAY.)

    • Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    • Lloyd KE, Hall LH, Ziegler L, Smith SG; ENGAGE investigators.
    • Breast Cancer Res Treat. 2021 Aug;188(3):703-712. doi: 10.1007/s10549-021-06183-x. Epub 2021 Mar 17.
    • Influential Factors on Risk-reduction Mastectomy in a High-risk Breast Cancer Population With Genetic Predispositions.
    • Wei G, Kumar A, Lee MC, Wang X.
    • Clin Breast Cancer. 2021 Aug;21(4):e427-e433. doi: 10.1016/j.clbc.2021.01.008. Epub 2021 Jan 19.
    • Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    • Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM.
    • Sci Rep. 2021 Jul 20;11(1):14747. doi: 10.1038/s41598-021-94195-4.
    • Decision aids for female BRCA mutation carriers: a scoping review protocol.
    • McGarrigle SA, Prizeman G, Spillane C, Byrne N, Drury A, Mockler D, Connolly EM, Brady AM, Hanhauser YP.
    • BMJ Open. 2021 Jul 12;11(7):e045075. doi: 10.1136/bmjopen-2020-045075.
    • Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma.
    • Everett JN, Burgos G, Chun J, Baptiste A, Khanna LG, Oberstein PE, Simeone DM.
    • Cancer. 2021 Jul 1;127(13):2271-2278. doi: 10.1002/cncr.33500. Epub 2021 Mar 15.
    • Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    • Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ.
    • NPJ Breast Cancer. 2021 Jun 17;7(1):78. doi: 10.1038/s41523-021-00288-8.
    • Why I’m Choosing to Keep My Breasts (For Now).
    • Kingery R.
    • FORCE. Blog. 2021 Jun 11.
    • Living Life to its Fullest with an ATM Mutation in a Coronavirus Pandemic.
    • Sandhu S.
    • FORCE. Blog. 2021 Jun 11.
    • Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
    • Kautz-Freimuth S, Redaèlli M, Rhiem K, Vodermaier A, Krassuski L, Nicolai K, Schnepper M, Kuboth V, Dick J, Vennedey V, Wiedemann R, Schmutzler R, Stock S.
    • BMC Med Inform Decis Mak. 2021 Jun 5;21(1):180. doi: 10.1186/s12911-021-01528-4.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review.
    • Krassuski LM, Kautz-Freimuth S, Vennedey V, Rhiem K, Schmutzler RK, Stock S.
    • Geburtshilfe Frauenheilkd. 2021 Jun;81(6):679-698. doi: 10.1055/a-1326-1792. Epub 2021 Jun 21.
    • Genetic Testing Challenges in Oncology: Immigrant Mislabeled as BRCA-Positive, Regrets Ovary Removal.
    • Ray T.
    • Precision Oncology News. Diagnostics. Molecular Diagnostics. 2021 May 28.
    • Uncertainty following an inconclusive result from the BRCA1/2 genetic test: A review about psychological outcomes.
    • Bramanti SM, Trumello C, Lombardi L, Cavallo A, Stuppia L, Antonucci I, Babore A.
    • World J Psychiatry. 2021 May 19;11(5):189-200. doi: 10.5498/wjp.v11.i5.189.
    • Testing a best practices risk result format to communicate genetic risks.
    • Davis KW, Roter DL, Schmidlen T, Scheinfeldt LB, Klein WMP.
    • Patient Educ Couns. 2021 May;104(5):936-943. doi: 10.1016/j.pec.2020.10.021. Epub 2020 Oct 19.
    • How patients deal with an ambiguous medical test: Decision-making after genetic testing.
    • Scherr CL, Ramesh S, Getachew-Smith H, Kalke K, Ramsey K, Fischhoff B, Vadaparampil ST.
    • Patient Educ Couns. 2021 May;104(5):953-959. doi: 10.1016/j.pec.2020.10.020. Epub 2020 Oct 18.
    • Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
    • Haddad JM, Robison K, Beffa L, Laprise J, ScaliaWilbur J, Raker CA, Clark MA, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A.
    • J Genet Couns. 2021 Apr 27. doi: 10.1002/jgc4.1423. Epub ahead of print.
    • High-risk women are facing barriers to preventive breast cancer care.
    • Branigin A.
    • Washington Post. The Lily. 2021 Apr 27.

    Related:

    Original research:

    Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.

    • The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and/or fertility preservation strategies in premenopausal women with early breast cancer.
    • Blondeaux E, Massarotti C, Fontana V, Poggio F, Arecco L, Fregatti P, Bighin C, Giannubilo I, Ruelle T, Razeti MG, Boni L, Anserini P, Del Mastro L, Lambertini M.
    • Front Oncol. 2021 Apr 26;10:690320. doi: 10.3389/fonc.2021.690320.
    • Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer.
    • Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK.
    • Cancers (Basel). 2021 Apr 23;13(9):2050. doi: 10.3390/cancers13092050.
    • Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.
    • Makhnoon S, Bednar EM, Krause KJ, Peterson SK, Lopez-Olivo MA.
    • Clin Genet. 2021 Apr 12. doi: 10.1111/cge.13966. Epub ahead of print.
    • Review
    • Why So Many of Us Quit Taking Tamoxifen.
    • Horner K.
    • FORCE. Blog. 2021 Apr 6.

    Related:

    Research news: Study: How breast cancer patients experience hormone therapy (FORCE. XRAY.)

    • Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.
    • Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.
    • Int J Behav Med. 2021 Mar 31. doi: 10.1007/s12529-021-09984-y. Epub ahead of print.
    • Understanding Breast Implant Risks.
    • Spittal K.
    • FORCE. XRAY. 2021 Mar 30.
    • Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.
    • Meadows RJ, Padamsee TJ.
    • J Genet Couns. 2021 Mar 21. doi: 10.1002/jgc4.1413. Epub ahead of print.

    Related:

    Press: High-risk women are facing barriers to preventive breast cancer care. (Washington Post / The Lily)

    • Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    • Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vida JB, Kariv R, Rosner G, Piñero TA, Pavicic W, Kalfayan P, Ten Broeke SW, Jenkins MA, Sunde L, Bernstein I, Burn J, Greenblatt M, de Vos Tot Nederveen Cappel WH, Della Valle A, Lopez-Koestner F, Alvarez K, Büttner R, Görgens H, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Redler S, Weitz J, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Hopper JL, Win AK, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Therkildsen C, Wadt KAW, Mourits MJE, Ketabi Z, Denton OG, Rødland EA, Vasen H, Neffa F, Esperon P, Tjandra D, Möslein G, Rokkones E, Sampson JR, Evans DG, Møller P.
    • Eur J Cancer. 2021 Mar 17;148:124-133. doi: 10.1016/j.ejca.2021.02.022. Epub ahead of print.
    • Variations in breast cancer surgical treatment and timing: determinants and disparities.
    • Dankwa-Mullan I, George J, Roebuck MC, Tkacz J, Willis VC, Reyes F, Arriaga YE.
    • Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-021-06155-1. Epub ahead of print.
    • The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study.
    • Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.
    • Fam Cancer. 2021 Feb 19. doi: 10.1007/s10689-021-00232-6. Epub ahead of print.
    • (Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
    • Mink van der Molen DR, Bargon CA, Batenburg MCT, Gal R, Young-Afat DA, van Stam LE, van Dam IE, van der Leij F, Baas IO, Ernst MF, Maarse W, Vermulst N, Schoenmaeckers EJP, van Dalen T, Bijlsma RM, Doeksen A, Verkooijen HM; UMBRELLA study group.
    • Breast Cancer Res Treat. 2021 Feb 18. doi: 10.1007/s10549-021-06112-y. Epub ahead of print.
    • Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study.
    • Gaba F, Goyal S, Marks D, Chandrasekaran D, Evans O, Robbani S, Tyson C, Legood R, Saridogan E, McCluggage WG, Hanson H, Singh N, Evans DG, Menon U, Manchanda R; PROTECTOR team.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107501. doi: 10.1136/jmedgenet-2020-107501. Epub ahead of print.

    Related:

    Research news: Ovarian Cancer Prevention: How Patients Decide on Surgery. (Medscape)

    • The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.
    • Basu NN, Hodson J, Chatterjee S, Gandhi A, Wisely J, Harvey J, Highton L, Murphy J, Barnes N, Johnson R, Barr L, Kirwan CC, Howell S, Baildam AD, Howell A, Evans DG.
    • Sci Rep. 2021 Feb 2;11(1):2847. doi: 10.1038/s41598-021-82654-x.
    • Development and Implementation of an Algorithm to Guide MRI Screening in Patients With a Personal History of Treated Breast Cancer.
    • Strigel RM, Bravo E, Tevaarwerk AJ, Anderson BM, Stella AL, Neuman HB.
    • Clin Breast Cancer. 2021 Feb;21(1):26-30. doi: 10.1016/j.clbc.2020.01.005. Epub 2020 Oct 17.
    • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    • Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.
    • Clin Breast Cancer. 2021 Feb;21(1):e48-e52. doi: 10.1016/j.clbc.2020.08.004. Epub 2020 Aug 20.
    • Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing.
    • Gaddam S, Heller SL, Babb JS, Gao Y.
    • Clin Breast Cancer. 2021 Feb;21(1):e74-e79. doi: 10.1016/j.clbc.2020.07.014. Epub 2020 Jul 25.
    • Parent-Child Communication and Reproductive Considerations in Families with Genetic Cancer Predisposition Syndromes: A Systematic Review.
    • Dattilo TM, Lipak KG, Clark OE, Gehred A, Sampson A, Quinn G, Zajo K, Sutter ME, Bowman-Curci M, Gardner M, Gerhardt CA, Nahata L.
    • J Adolesc Young Adult Oncol. 2021 Feb;10(1):15-25. doi: 10.1089/jayao.2020.0084. Epub 2020 Sep 8.
    • Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?
    • Macadam SA, Slater K, Cheifetz RE, Jansen L, Chia S, Brasher PMA, Bovill ES.
    • Curr Oncol. 2021 Jan 25;28(1):702-715. doi: 10.3390/curroncol28010069.
    • Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
    • Geuzinge HA, Heijnsdijk EAM, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.
    • Breast. 2021 Jan 18;56:1-6. doi: 10.1016/j.breast.2021.01.002. Epub ahead of print.
    • Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    • Jones S, Hogan B, Patel K, Ooi S, Turton P, Achuthan R, Kim B.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06046-x. Epub ahead of print.
    • Breast Cancer Chemoprevention: Use and Views of Australian Women and their Clinicians.
    • Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, Jones SC, Nesci S, Friedlander ML, Hopper JL, Emery JD, Hickey M, Milne RL, Phillips KA; Kathleen Cuningham Consortium for Research Into Familial Breast Cancer.
    • Cancer Prev Res (Phila). 2021 Jan;14(1):131-144. doi: 10.1158/1940-6207.CAPR-20-0369. Epub 2020 Oct 28.

    Related:

    Commentary:

    Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue.

    • Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review.
    • Park SY, Kim Y, Kim S.
    • Korean J Women Health Nurs. 2020 Dec 31;26(4):285-299. doi: 10.4069/kjwhn.2020.11.19. Epub 2020 Dec 9.
    • The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
    • Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I.
    • Breast. 2020 Dec 24;55:98-104. doi: 10.1016/j.breast.2020.12.008. Epub ahead of print.
    • Study: Women support delayed removal of ovaries.
    • [No author given]
    • FORCE. XRAY. 2020 Dec 24.

    Related:

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • CA125 and Ovarian Cancer: A Comprehensive Review.
    • Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR.
    • Cancers (Basel). 2020 Dec 11;12(12):3730. doi: 10.3390/cancers12123730.
    • Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
    • Nahshon C, Segev Y, Gemer O, Bar Noy T, Schmidt M, Ostrovsky L, Lavie O.
    • Gynecol Oncol. 2020 Dec 9:S0090-8258(20)34162-7. doi: 10.1016/j.ygyno.2020.11.034. Epub ahead of print.
    • Review
    • My Previvor Journey: My Robotic Mastectomy.
    • Mallonee R.
    • FORCE. Blog. 2020 Dec 7.
    • Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):3543. doi: 10.3390/cancers12123543.
    • Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".
    • Lowry KP, Sippo DA.
    • AJR Am J Roentgenol. 2020 Nov 25. doi: 10.2214/AJR.20.25138. Epub ahead of print.
    • Commentary

    Related:

    Original research:

    Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.

    • Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program.
    • Warner E, Zhu S, Plewes DB, Hill K, Ramsay EA, Causer PA, Seely J, Jong RA, Lenkov P, Elser C, Crystal P, Yaffe MJ, Giannakeas V, Sun P, Narod SA.
    • Cancers (Basel). 2020 Nov 23;12(11):3479. doi: 10.3390/cancers12113479.
    • Expanded Panel Testing Uncovered My ATM Mutation.
    • Horton M.
    • FORCE. Blog. 2020 Nov 23.
    • Finding Hope on the Other Side of Surgery After Learning of my ATM Mutation.
    • Townsend C.
    • FORCE. Blog. 2020 Nov 13.
    • An ATM Gene Mutation Caused My Breast Cancer
    • Cohen E.
    • FORCE. Blog. 2020 Nov 12.
    • Previvor at 25 - The Beginning has just Begun.
    • Wilson L.
    • FORCE. Blog. 2020 Nov 10.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Related:

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest.
    • Worcester S.
    • Medscape. News & Perspective. 2020 Oct 16.

    Related:

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    • Fadda M, Chappuis PO, Katapodi MC, Pagani O, Monnerat C, Membrez V, Unger S, Caiata Zufferey M.
    • PLoS One. 2020 Oct 8;15(10):e0240054. doi: 10.1371/journal.pone.0240054.
    • BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
    • Lynce F, Schlam I, Geng X, Peshkin BN, Friedman S, Dutil J, Nahleh Z, Campos C, Ricker C, Rodriguez P, Denduluri N, Ahn J, Isaacs C, Graves KD.
    • J Genet Couns. 2020 Oct 3. doi: 10.1002/jgc4.1322. Epub ahead of print.
    • Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.
    • Forrest LE, Shepherd RF, Young MA, Keogh LA, James PA.
    • Psychooncology. 2020 Oct 1. doi: 10.1002/pon.5556. Epub ahead of print.
    • Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
    • Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A.
    • Hered Cancer Clin Pract. 2020 Sep 29;18:20. doi: 10.1186/s13053-020-00152-z.
    • Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
    • Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari M, Narod SA.
    • Ann Surg Oncol. 2020 Sep 28. doi: 10.1245/s10434-020-09160-8. Epub ahead of print.
    • Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
    • Trister R, Jacobson M, Nguyen P, Sobel M, Allen L, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2020 Sep 23. doi: 10.1007/s10689-020-00208-y. Epub ahead of print.
    • Cardiovascular Prevention in Individuals at High Risk of Developing Cancer.
    • Oren O, Kopecky SL, Blumenthal RS, Gersh BJ, Yang EH.
    • JACC CardioOncol. 2020 Sep 15;2(3):527-531. doi: 10.1016/j.jaccao.2020.07.002.
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making.
    • Reumkens K, Tummers MHE, Severijns Y, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets M, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM.
    • J Community Genet. 2020 Sep 2. doi: 10.1007/s12687-020-00484-2. Epub ahead of print.
    • Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    • Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van 't Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ; Familial MRI Screening (FaMRIsc) Study group.
    • JAMA Oncol. 2020 Sep 1;6(9):1381-1389. doi: 10.1001/jamaoncol.2020.2922.

    Related:

    Commentary:

    Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".

    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Related:

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    • Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon U, Manchanda R.
    • BJOG. 2020 Aug 16. doi: 10.1111/1471-0528.16424. Epub ahead of print.

    Related:

    Commentary:

    Attitudes towards risk-reducing salpingectomy: listen to the patients.

    Press: Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest (Medscape. News & Perspective.)

    Research news: Study: Women support delayed removal of ovaries (FORCE. XRAY.)

    • Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    • Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2020 Aug 10. doi: 10.1097/GME.0000000000001629. Epub ahead of print.
    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review
    • Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
    • Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I.
    • Ann Surg Oncol. 2020 Jul 27. doi: 10.1245/s10434-020-08889-6. Epub ahead of print.
    • Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
    • Collins JM, Isaacs C.
    • Breast J. 2020 Jul 11. doi: 10.1111/tbj.13970. Epub ahead of print.
    • Review
    • How to Prepare for a Mastectomy Amid COVID and Other Life Events.
    • Wheaton J.
    • FORCE Blog. 2020 Jul 8.
    • Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland.
    • Karwacki MW.
    • Contemp Oncol (Pozn). 2020;24(2):140-144. doi: 10.5114/wo.2020.97637. Epub 2020 Jul 3.
    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Related:

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    • Scherr CL, Ross Arguedas AA, Getachew-Smith H, Marshall-Fricker C, Shrestha N, Brooks K, Fischhoff B, Vadaparampil ST.
    • Med Decis Making. 2020 Jul;40(5):655-668. doi: 10.1177/0272989X20935864.
    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Related:

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
    • Isselhard A, Töpper M, Berger-Höger B, Steckelberg A, Fischer H, Vitinius F, Beifus K, Köberlein-Neu J, Wiedemann R, Rhiem K, Schmutzler R, Stock S.
    • Trials. 2020 Jun 8;21(1):501. doi: 10.1186/s13063-020-04431-x.
    • Factors Impacting on Decision-Making towards Prophylactic Surgeries in BRCA Mutation Carriers and Women with Familial Predisposition.
    • Segerer R, Peschel C, Kämmerer U, Häussler S, Wöckel A, Segerer S.
    • Breast Care (Basel). 2020 Jun;15(3):253-259. doi: 10.1159/000503370. Epub 2019 Oct 1.
    • Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
    • Dean M, Campbell-Salome G, Rauscher EA.
    • Am J Mens Health. 2020 May-Jun;14(3):1557988320924932. doi: 10.1177/1557988320924932.
    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.
    • Comparison of mammography behaviors, health beliefs, and fear levels of women with and without familial breast cancer history.
    • Erdogan E, Tuzcu A.
    • Women Health. 2020 Apr 6:1-16. doi: 10.1080/03630242.2020.1746949. [Epub ahead of print]
    • Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers.
    • Tan MP.
    • Br J Radiol. 2020 Apr;93(1108):20200038. doi: 10.1259/bjr.20200038. Epub 2020 Feb 26.
    • Letter, Comment

    Related:

    Review:

    Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.

    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Knowledge and attitude of hereditary breast cancer among Japanese university female students.
    • Terui-Kohbata H, Egawa M, Yura K, Yoshida M.
    • J Hum Genet. 2020 Mar 18. doi: 10.1038/s10038-020-0743-9. [Epub ahead of print]
    • Hormone Replacement Therapy Prescription After Premature Surgical Menopause.
    • Garg N, Behbehani S, Kosiorek H, Wasson M.
    • J Minim Invasive Gynecol. 2020 Mar 12. pii: S1553-4650(20)30124-2. doi: 10.1016/j.jmig.2020.03.002. [Epub ahead of print]
    • Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
    • Ghezelayagh TS, Stewart LE, Norquist BM, Bowen DJ, Yu V, Agnew KJ, Pennington KP, Swisher EM.
    • Fam Cancer. 2020 Feb 24. doi: 10.1007/s10689-020-00166-5. [Epub ahead of print]
    • Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
    • Napoli M, Lewis J, Hopper J, Widmeyer K.
    • J Genet Couns. 2020 Feb 3. doi: 10.1002/jgc4.1220. [Epub ahead of print]
    • Family storytelling about hereditary cancer: Framing shared understandings of risk.
    • Campbell-Salome G, Rauscher EA.
    • J Genet Couns. 2020 Jan 22. doi: 10.1002/jgc4.1218. [Epub ahead of print]
    • Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.
    • Teoh V, Tasoulis MK, Gui G.
    • Cancers (Basel). 2020 Jan 6;12(1). pii: E140. doi: 10.3390/cancers12010140.
    • Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    • Tynan M, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill SC, Jandorf L, Kelly SP, Heinzmann J, Kelleher S, Poggi E, Schwartz MD.
    • Breast Cancer Res Treat. 2020 Jan 1. doi: 10.1007/s10549-019-05515-2. [Epub ahead of print]
    • A Genetic Test Led Seven Women in One Family to Have Major Surgery. Then the Odds Changed.
    • Marcus AD.
    • The Wall Street Journal. 2019 Dec 20.
    • Press

    Related:

    Press: Downgraded Variant. (GenomeWeb)

    • Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors.
    • Samimi G, Heckman-Stoddard BM, Holmberg C, Tennant B, Sheppard BB, Coa KI, Kay SS, Ford LG, Szabo E, Minasian LM.
    • Am J Med. 2019 Dec 17. pii: S0002-9343(19)31095-2. doi: 10.1016/j.amjmed.2019.11.017. [Epub ahead of print]
    • Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers.
    • van Egdom LSE, de Kock MA, Apon I, Mureau MAM, Verhoef C, Hazelzet JA, Koppert LB.
    • Breast Cancer. 2019 Dec 12. doi: 10.1007/s12282-019-01033-7. [Epub ahead of print]
    • BRCA and Motherhood: A Matter of Time and Timing.
    • Possick C, Kestler-Peleg M.
    • Qual Health Res. 2019 Dec 7:1049732319885113. doi: 10.1177/1049732319885113. [Epub ahead of print]
    • Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
    • Sardanelli F, Cozzi A, Trimboli RM, Schiaffino S.
    • AJR Am J Roentgenol. 2019 Dec 4:1-4. doi: 10.2214/AJR.19.21988. [Epub ahead of print]
    • Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
    • Swanson CL, Bakkum-Gamez JN.
    • Clin Obstet Gynecol. 2019 Nov 22. doi: 10.1097/GRF.0000000000000499. [Epub ahead of print]
    • Review
    • Men With BRCA2 Should Be Screened for Prostate Cancer.
    • Davenport L.
    • Medscape Oncology. 2019 Nov 8.

    Related:

    Original research:

    Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • "How do we rally around the one who was positive?" Familial uncertainty management in the context of men managing BRCA-related cancer risks.
    • Rauscher EA, Dean M, Campbell-Salome G, Barbour JB.
    • Soc Sci Med. 2019 Oct 11;242:112592. doi: 10.1016/j.socscimed.2019.112592. [Epub ahead of print]
    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    • Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Mahle L, Grindedal EMM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA.
    • Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30668-2. doi: 10.1016/j.eururo.2019.08.019. [Epub ahead of print]

    Related:

    Research news, Conference report: Men With BRCA2 Should Be Screened for Prostate Cancer. (Medscape)

    Research news: The IMPACT of BRCA2 in prostate cancer. (Nature Reviews Urology)

    • Patient-physician relationships, health self-efficacy, and gynecologic cancer screening among women with Lynch syndrome.
    • McGarragle KM, Aronson M, Semotiuk K, Holter S, Hare CJ, Ferguson SE, Cohen Z, Hart TL.
    • Hered Cancer Clin Pract. 2019 Aug 13;17:24. doi: 10.1186/s13053-019-0123-7. eCollection 2019.
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    • Krassuski L, Vennedey V, Stock S, Kautz-Freimuth S.
    • BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer.
    • Guan Y, Nehl E, Pencea I, Condit CM, Escoffery C, Bellcross CA, McBride CM.
    • Sci Rep. 2019 Jul 3;9(1):9599. doi: 10.1038/s41598-019-45967-6.
    • Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice?
    • Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C.
    • Psychooncology. 2019 Jul 1. doi: 10.1002/pon.5166. [Epub ahead of print]
    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Related:

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • A young woman's story of genetic testing and risk-reducing mastectomy.
    • [No author given]
    • FORCE. XRAYS. 2019 Jun 6.

    Related:

    Narrative: I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer. (Health)

    • Choosing high-risk screening vs. surgery and the effect of treatment modality on anxiety and breast-specific sensuality in BRCA mutation carriers.
    • Rojas KE, Butler E, Gutierrez J, Kwait R, Laprise J, Wilbur JS, Spinette S, Raker CA, Robison K, Legare R, Gass J, Stuckey A.
    • Gland Surg. 2019 Jun;8(3):249-257. doi: 10.21037/gs.2019.04.08.
    • Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making.
    • Reumkens K, Tummers MHE, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets CM, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T1, de Die-Smulders CEM, van Osch LADM.
    • J Genet Couns. 2019 Jun;28(3):533-542. doi: 10.1002/jgc4.1056. Epub 2018 Dec 21.
    • NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program.
    • Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, Schachter NF, McCuaig JM, Kim RH.
    • Cancers (Basel). 2019 May 22;11(5). pii: E707. doi: 10.3390/cancers11050707.
    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Understanding BRCA Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk.
    • Hovick SR, Tan N, Morr L, Senter L, Kinnamon DD, Pyatt RE, Toland AE.
    • J Health Commun. 2019 May 6:1-8. doi: 10.1080/10810730.2019.1604912. [Epub ahead of print]
    • Accuracy in risk understanding among BRCA1/2-mutation carriers.
    • Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F.
    • Patient Educ Couns. 2019 May 5. pii: S0738-3991(18)30887-5. doi: 10.1016/j.pec.2019.05.007. [Epub ahead of print]
    • Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy.
    • Manne S, Smith B, Mitarotondo A, Frederick S, Toppmeyer D, Kirstein L.
    • Patient Educ Couns. 2019 May;102(5):902-908. doi: 10.1016/j.pec.2018.12.008. Epub 2018 Dec 10.
    • Factors associated with intentions for breast cancer risk management: Does risk group matter?
    • Conley CC, Agnese DM, Vadaparampil ST, Andersen BL.
    • Psychooncology. 2019 May;28(5):1119-1126. doi: 10.1002/pon.5066. Epub 2019 Apr 10.
    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers.
    • Yost S, Ruark E, Alexandrov LB, Rahman N.
    • JNCI Cancer Spectr. 2019 Apr 19;3(2):pkz028. doi: 10.1093/jncics/pkz028. eCollection 2019 Jun.
    • "It felt like unfinished business, it feels like that's finished now": Women's experiences of decision making around Contralateral Prophylactic Mastectomy (CPM).
    • Tollow P, Williams VS, Harcourt D, Paraskeva N.
    • Psychooncology. 2019 Apr 8. doi: 10.1002/pon.5086. [Epub ahead of print]
    • Predictive Power of PEN-3 Model Constructs in Breast Cancer Screening Behaviors among Teachers: A Cross- Sectional Study in Central Iran.
    • Moghaddam ES, Shahnazi H, Hassanzadeh A.
    • Eur J Breast Health. 2019 Apr 1;15(2):105-110. doi: 10.5152/ejbh.2019.4417. eCollection 2019 Apr.
    • What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.
    • Franceschini G, Masetti R.
    • Eur J Breast Health. 2019 Apr 1;15(2):135-136. doi: 10.5152/ejbh.2019.4651. eCollection 2019 Apr.

    Related:

    Review:

    Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

    • Exploring the preferences of involved health professionals regarding the implementation of an online decision aid to support couples during reproductive decision-making in hereditary cancer: a mixed methods approach.
    • Reumkens K, de Die-Smulders CEM, van Osch LADM.
    • Fam Cancer. 2019 Apr;18(2):285-291. doi: 10.1007/s10689-019-00119-7.
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Related:

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Risk perception and screening behavior of Filipino women at risk for breast cancer: implications for cancer genetic counseling.
    • Lagarde JBB, Laurino MY, San Juan MD, Cauyan JML, Tumulak MJR, Ventura ER.
    • J Community Genet. 2019 Apr;10(2):281-289. doi: 10.1007/s12687-018-0391-3. Epub 2018 Sep 27.
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Related:

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome.
    • Modaffari P, Ponzone R, Ferrari A, Cipullo I, Liberale V, D'Alonzo M, Maggiorotto F, Biglia N.
    • J Clin Med. 2019 Mar 5;8(3). pii: E313. doi: 10.3390/jcm8030313.
    • Chemoprevention acceptance and adherence in women with high-risk breast lesions.
    • Roche CA, Tang R, Coopey SB, Hughes KS.
    • Breast J. 2019 Mar;25(2):190-195. doi: 10.1111/tbj.13064. Epub 2018 May 21

    Related:

    Editorial:

    Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.

    Press: Chemoprevention of Breast Cancer: Personal Touch Helps Uptake. (Medscape Oncology)

    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Related:

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    • Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC, Laronga C.
    • Breast Cancer Res Treat. 2019 Feb;174(1):39-45. doi: 10.1007/s10549-018-5057-7. Epub 2018 Nov 24.
    • The impact of variant classification on the clinical management of hereditary cancer syndromes.
    • Turner SA, Rao SK, Morgan RH, Vnencak-Jones CL, Wiesner GL.
    • Genet Med. 2019 Feb;21(2):426-430. doi: 10.1038/s41436-018-0063-z. Epub 2018 Jun 6.
    • Legacies and Relationships: Diverse Social Networks and BRCA1/2 Risk Management Decisions and Actions.
    • Ersig AL, Werner-Lin A, Hoskins L, Young J, Loud JT, Peters J, Greene MH.
    • J Fam Nurs. 2019 Feb;25(1):28-53. doi: 10.1177/1074840718815844. Epub 2018 Dec 12.
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift.
    • Møller P, Dominguez-Valentin M, Rødland EA, Hovig E.
    • Cancers (Basel). 2019 Jan 23;11(2). pii: E132. doi: 10.3390/cancers11020132.
    • Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.
    • Jabaley T, Underhill-Blazey ML, Berry DL.
    • J Cancer Educ. 2019 Jan 19. doi: 10.1007/s13187-019-1470-9. [Epub ahead of print]
    • The Impact of a Risk-Based Breast Cancer Screening Decision Aid on Initiation of Mammography Among Younger Women: Report of a Randomized Trial.
    • Schapira MM, Hubbard RA, Seitz HH, Conant EF, Schnall M, Cappella JN, Harrington T, Inge C, Armstrong K.
    • MDM Policy Pract. 2019 Jan 17;4(1):2381468318812889. doi: 10.1177/2381468318812889. eCollection 2019 Jan-Jun.
    • Helping Patients Manage the Anxiety Behind Contralateral Prophylactic Mastectomy.
    • Schapira L, Parker P.
    • Medscape. Medscape Oncology. 2019 Jan 17.

    Related:

    Original research:

    Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.

    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study.
    • Reumkens K, Tummers MHE, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets CM, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM.
    • Fam Cancer. 2019 Jan;18(1):137-146. doi: 10.1007/s10689-018-0092-4.
    • Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer.
    • Schwartz LA, Henry-Moss D, Egleston B, Patrick-Miller L, Markman E, Daly M, Tuchman L, Moore C, Rauch PK, Karpink K, Sands CB, Domchek SM, Bradbury AR.
    • J Adolesc Health. 2019 Jan;64(1):116-123. doi: 10.1016/j.jadohealth.2018.07.011. Epub 2018 Oct 6.
    • Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    • Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.
    • Ann Ital Chir. 2019;90:1-2.
    • Review
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Related:

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge.
    • Machirori M, Patch C, Metcalfe A.
    • Eur J Med Genet. 2018 Dec 12. pii: S1769-7212(18)30405-1. doi: 10.1016/j.ejmg.2018.12.006. [Epub ahead of print]
    • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.
    • Narod SA.
    • JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931.
    • Letter, Comment

    Related:

    Original Research:

    Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    Letter, reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • "I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
    • Rauscher EA, Dean M, Campbell-Salome GM.
    • J Genet Couns. 2018 Dec;27(6):1417-1427. doi: 10.1007/s10897-018-0276-y. Epub 2018 Jul 3.
    • The influence of Malay cultural beliefs on breast cancer screening and genetic testing: A focus group study.
    • Shaw T, Ishak D, Lie D, Menon S, Courtney E, Li ST, Ngeow J.
    • Psychooncology. 2018 Dec;27(12):2855-2861. doi: 10.1002/pon.4902. Epub 2018 Oct 16.
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
    • Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.
    • JCO Precis Oncol. [2018 Nov 8];2:1-10. doi: 10.1200/PO.18.00167.
    • A randomized controlled trial of a supportive expressive group intervention for women with a family history of breast cancer.
    • Esplen MJ, Leszcz M, Hunter J, Wong J, Leung YW, Toner B, Messner S, Glendon G, Stuckless N, Butler C.
    • Psychooncology. 2018 Nov;27(11):2645-2653. doi: 10.1002/pon.4822. Epub 2018 Jul 17.
    • Hysterectomy at the time of risk-reducing surgery in BRCA carriers.
    • Nair N, Schwartz M, Guzzardi L, Durlester N, Pan S, Overbey J, Chuang L.
    • Gynecol Oncol Rep. 2018 Oct 6;26:71-74. doi: 10.1016/j.gore.2018.10.003. eCollection 2018 Nov.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Cancer experience in families affects decision making.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 25.

    Related:

    Press: How a Loved One’s Experience With Cancer Guides Breast Cancer Decisions. (U.S. News & World Report)

    • Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.
    • Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS.
    • J Natl Cancer Inst. 2018 Sep 1;110(9):985-993. doi: 10.1093/jnci/djy015.
    • Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations.
    • Werner-Lin A, Ersig AL, Mueller R, Young JL, Hoskins LM, Desai R, Greene MH.
    • J Psychosoc Oncol. 2018 Sep-Oct;36(5):529-544. doi: 10.1080/07347332.2018.1469565. Epub 2018 Jun 4.
    • Factors associated with breast MRI use among women with a family history of breast cancer.
    • White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.
    • Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.
    • Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
    • Puski A, Hovick S, Senter L, Toland AE4.
    • J Genet Couns. 2018 Sep;27(5):1291-1301. doi: 10.1007/s10897-018-0254-4. Epub 2018 Mar 29.
    • Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".
    • Cox DM.
    • J Genet Couns. 2018 Sep;27(5):1312-1313. doi: 10.1007/s10897-018-0280-2. Epub 2018 Jul 21.
    • Letter

    Related:

    A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes.
    • Weiss A, Garber JE, King T.
    • JAMA Surg. 2018 Aug 29. doi: 10.1001/jamasurg.2018.2493. [Epub ahead of print]
    • Review
    • Patients' perspectives and experiences concerning barriers to accessing information about bilateral prophylactic mastectomy.
    • Glassey R, O'Connor M, Ives A, Saunders C, kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Breast. 2018 Aug;40:116-122. doi: 10.1016/j.breast.2018.05.003. Epub 2018 May 11.
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
    • Hesse-Biber S, Flynn B, Farrelly K.
    • Qual Health Res. 2018 Aug;28(10):1523-1538. doi: 10.1177/1049732318767395. Epub 2018 Apr 11.
    • Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer.
    • Yadav S, Jinna S, Pereira-Rodrigues O, Reeves A, Campian S, Sufka A, Zakalik D.
    • Breast J. 2018 Jul;24(4):541-548. doi: 10.1111/tbj.13007. Epub 2018 Mar 2.
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Support needs of couples with hereditary breast and ovarian cancer during reproductive decision-making.
    • Gietel-Habets JJG, de Die-Smulders CEM, Derks-Smeets IAP, Tibben A, Tjan-Heijnen VCG, van Golde R, Gomez-Garcia E, van Osch LADM.
    • Psychooncology. 2018 Jul;27(7):1795-1801. doi: 10.1002/pon.4729. Epub 2018 May 4.
    • Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
    • Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK.
    • Cancer Med. 2018 Jun;7(6):2718-2726. doi: 10.1002/cam4.1519. Epub 2018 May 7.
    • Nipple-sparing mastectomy in women at high risk of developing breast cancer.
    • Lewis RS, George A, Rusby JE.
    • Gland Surg. 2018 Jun;7(3):325-336. doi: 10.21037/gs.2018.04.01.
    • A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
    • Harmsen MG, Steenbeek MP, Hoogerbrugge N, van Doorn HC, Gaarenstroom KN, Vos MC, Massuger LFAG, de Hullu JA, Hermens RPMG.
    • Health Expect. 2018 Jun;21(3):659-667. doi: 10.1111/hex.12661. Epub 2017 Dec 27.
    • Juliet's story: No reconstruction is a post-mastectomy option.
    • [No author given]
    • FORCE. XRAYS. 2018 May 24.

    Related:

    Blog post: I felt empowered by choosing not to have a reconstruction. (Breast Cancer Care)

    • Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants.
    • Buchanan AH, Manickam K, Meyer MN, Wagner JK, Hallquist MLG, Williams JL, Rahm AK, Williams MS, Chen ZE, Shah CK, Garg TK, Lazzeri AL, Schwartz MLB, Lindbuchler DM, Fan AL, Leeming R, Servano PO 3rd, Smith AL, Vogel VG, Abul-Husn NS, Dewey FE, Lebo MS, Mason-Suares HM, Ritchie MD, Davis FD, Carey DJ, Feinberg DT, Faucett WA, Ledbetter DH, Murray MF.
    • Genet Med. [2018 May;]20(5):554-558. doi: 10.1038/gim.2017.145. Epub 2017 Oct 26.
    • Complex Medical Decision-Making for a Trans-Feminine Youth with a BRCA1 Mutation.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):221-225. doi: 10.1089/lgbt.2017.0149.
    • Case report
    • Risk management decisions in women with BRCA1 and BRCA2 mutations.
    • Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.
    • Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.
    • Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
    • Grimmett C, Pickett K, Shepherd J, Welch K, Recio-Saucedo A, Streit E, Seers H, Armstrong A, Cutress RI, Evans DG, Copson E, Meiser B, Eccles D, Foster C.
    • Patient Educ Couns. 2018 May;101(5):779-788. doi: 10.1016/j.pec.2017.11.016. Epub 2017 Nov 26.
    • Review
    • Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer.
    • Park S, Lee JE, Ryu JM, Kim I, Bae SY, Lee SK, Yu J, Kim SW, Nam SJ.
    • World J Surg. 2018 May;42(5):1384-1390. doi: 10.1007/s00268-017-4342-7.
    • Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability Study.
    • Katapodi MC, Jung M, Schafenacker AM, Milliron KJ, Mendelsohn-Victor KE, Merajver SD, Northouse LL.
    • JMIR Cancer. 2018 Apr 13;4(1):e7. doi: 10.2196/cancer.9210.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
    • Scherr CL, Feuston JL, Nixon DM, Cohen SA.
    • J Genet Couns. 2018 Apr;27(2):439-445. doi: 10.1007/s10897-018-0222-z. Epub 2018 Feb 8.
    • An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data.
    • Cohen SA, Scherr CL, Nixon DM.
    • J Genet Couns. 2018 Apr;27(2):446-456. doi: 10.1007/s10897-018-0224-x. Epub 2018 Feb 10.
    • Take your time, follow your heart: strategies for communication about family planning.
    • [No author given]
    • FORCE. XRAYS. 2018 Mar 28.

    Related:

    "Take your time, then follow your heart:" Previvors' advice for communicating about family planning after testing positive for a BRCA genetic variant.

    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Adherence to Mediterranean Diet and Metabolic Syndrome in BRCA Mutation Carriers.
    • Bruno E, Manoukian S, Venturelli E, Oliverio A, Rovera F, Iula G, Morelli D, Peissel B, Azzolini J, Roveda E, Pasanisi P.
    • Integr Cancer Ther. 2018 Mar;17(1):153-160. doi: 10.1177/1534735417721015. Epub 2017 Jul 25.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Previvors' Uncertainty Management Strategies for Hereditary Breast and Ovarian Cancer.
    • Dean M, Davidson LG.
    • Health Commun. 2018 Feb;33(2):122-130. doi: 10.1080/10410236.2016.1250187. Epub 2016 Dec 15.
    • "I've just never gotten around to doing it": Men's approaches to managing BRCA-related cancer risks.
    • Rauscher EA, Dean M.
    • Patient Educ Couns. 2018 Feb;101(2):340-345. doi: 10.1016/j.pec.2017.07.015. Epub 2017 Jul 23.
    • Men seeking counselling in a Breast Cancer Risk Evaluation Clinic.
    • Freitas AC1, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F.
    • Ecancermedicalscience. 2018 Jan 30;12:804. doi: 10.3332/ecancer.2018.804. eCollection 2018.
    • Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors.
    • Kırca N, Tuzcu A, Gözüm S.
    • Eur J Breast Health. 2018 Jan 1;14(1):23-28. doi: 10.5152/ejbh.2017.3272. eCollection 2018 Jan.
    • Quality-of-life implications of risk-reducing cancer surgery.
    • Altman AM, Hui JYC, Tuttle TM.
    • Br J Surg. 2018 Jan;105(2):e121-e130. doi: 10.1002/bjs.10725.
    • Heightened perception of breast cancer risk in young women at risk of familial breast cancer.
    • Glassey R, O'Connor M, Ives A, Saunders C; kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Fam Cancer. 2018 Jan;17(1):15-22. doi: 10.1007/s10689-017-0001-2.
    • Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.
    • Padamsee TJ, Muraveva A, Yee LD, Wills CE, Paskett ED.
    • J Health Psychol. 2017 Dec 1:1359105317746480. doi: 10.1177/1359105317746480. [Epub ahead of print]
    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • "Take your time, then follow your heart:" Previvors' advice for communicating about family planning after testing positive for a BRCA genetic variant.
    • Rauscher EA, Dean M.
    • Fam Syst Health. 2017 Dec;35(4):486-497. doi: 10.1037/fsh0000312.

    Related:

    Research news: Take your time, follow your heart: strategies for communication about family planning. (FORCE. XRAYS.)

    • When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    • Speight B, Tischkowitz M.
    • J Genet Couns. 2017 Dec;26(6):1173-1178. doi: 10.1007/s10897-017-0136-1. Epub 2017 Aug 5.
    • "It was an Emotional Baby": Previvors' Family Planning Decision-Making Styles about Hereditary Breast and Ovarian Cancer Risk.
    • Dean M, Rauscher EA.
    • J Genet Couns. 2017 Dec;26(6):1301-1313. doi: 10.1007/s10897-017-0069-8. Epub 2017 Jan 30.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Psychosocial Aspects of Cancer Risk Management for Hereditary Breast and Ovarian Cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Behavioral Outcomes.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    • Wong XY, Chong KJ, van Til JA, Wee HL.
    • BMC Cancer. 2017 Nov 21;17(1):776. doi: 10.1186/s12885-017-3781-8.
    • Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
    • O'Quigley J.
    • Ann Epidemiol. 2017 Oct;27(10):672-676. doi: 10.1016/j.annepidem.2017.09.005. Epub 2017 Sep 20.
    • Review
    • Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
    • Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.
    • Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.
    • Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    • Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
    • A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.
    • Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L.
    • J Genet Couns. 2017 Oct;26(5):1144-1152. doi: 10.1007/s10897-017-0093-8. Epub 2017 Mar 23.

    Related:

    Letter:

    Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    • Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R5, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.
    • JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    • Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    • Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.
    • Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.
    • Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up.
    • Interrante MK, Segal H, Peshkin BN, Valdimarsdottir HB, Nusbaum R, Similuk M, DeMarco T, Hooker G, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Heinzmann J, Kinney AY, Schwartz MD.
    • JNCI Cancer Spectr. 2017 Sep;1(1):pkx002. doi: 10.1093/jncics/pkx002. Epub 2017 Sep 22.
    • How do women at increased breast cancer risk perceive and decide between risks of cancer and risk-reducing treatments? A synthesis of qualitative research.
    • Fielden HG, Brown SL, Saini P, Beesley H, Salmon P.
    • Psychooncology. 2017 Sep;26(9):1254-1262. doi: 10.1002/pon.4349. Epub 2017 Jan 26.
    • Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    • Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ.
    • J Clin Oncol. 2017 Jul 10;35(20):2232-2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12.

    Related:

    Press: Lack of Understanding of Genetic Breast Cancer Testing. (Medscape)

    • Longitudinal cancer risk management trajectories of BRCA1/2 mutation-positive reproductive-age women.
    • Young JL, Werner-Lin A, Mueller R, Hoskins L, Epstein N, Greene MH.
    • J Psychosoc Oncol. 2017 Jul-Aug;35(4):393-408. doi: 10.1080/07347332.2017.1292574. Epub 2017 Feb 14.
    • Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    • Johns D, Agarwal J, Anderson L, Ying J, Kohlmann W.
    • J Womens Health (Larchmt). 2017 Jun;26(6):702-706. doi: 10.1089/jwh.2016.5931. Epub 2016 Dec 6.
    • Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    • Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.
    • Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.
    • Decision making for breast cancer prevention among women at elevated risk.
    • Padamsee TJ, Wills CE, Yee LD, Paskett ED.
    • Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
    • Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
    • Metcalfe KA, Dennis CL, Poll A, Armel S, Demsky R, Carlsson L, Nanda S, Kiss A, Narod SA.
    • Genet Med. 2017 Mar;19(3):330-336. doi: 10.1038/gim.2016.108. Epub 2016 Sep 1.
    • [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
    • Kida K, Murai M, Yamauchi H.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):111-115.
    • Review, [Article in Japanese]
    • Commentary: Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers.
    • Glassey R, Saunders C, Hardcastle SJ.
    • Front Psychol. 2017 Jan 31;8:121. doi: 10.3389/fpsyg.2017.00121. eCollection 2017.

    Related:

    Review:

    Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers

    • Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
    • Myklebust M, Gjengedal E, Strømsvik N.
    • J Genet Couns. 2016 Dec;25(6):1198-1206. Epub 2016 Apr 19.
    • When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.
    • Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G.
    • Eur J Hum Genet. 2016 Nov;24(11):1517-1523. doi: 10.1038/ejhg.2016.69. Epub 2016 Jun 22.
    • Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    • Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2016 Oct;23(10):3232-8. doi: 10.1245/s10434-016-5328-7. Epub 2016 Jun 23.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Impact of Timing of BRCA Testing

    • Trends in Media Reports of Celebrities' Breast Cancer Treatment Decisions.
    • Sabel MS, Cin SD.
    • Ann Surg Oncol. 2016 Sep;23(9):2795-801. doi: 10.1245/s10434-016-5202-7. Epub 2016 Apr 6.
    • Counselling framework for moderate-penetrance cancer-susceptibility mutations.
    • Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME.
    • Nat Rev Clin Oncol. 2016 Sep;13(9):581-8. doi: 10.1038/nrclinonc.2016.90. Epub 2016 Jun 14.
    • Review
    • The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening.
    • Smits S, Boivin J, Menon U, Brain K.
    • Ecancermedicalscience. 2016 Jun 30;10:650. doi: 10.3332/ecancer.2016.650. eCollection 2016.
    • Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support.
    • Evans C, Hamilton RJ, Tercyak KP, Peshkin BN, Rabemananjara K, Isaacs C, O'Neill SC.
    • Healthcare (Basel). 2016 Jun 28;4(3). pii: E35. doi: 10.3390/healthcare4030035.
    • Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    • Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Evers C, Dikow N, Sohn C, Heil J, Schott S.
    • Breast Cancer Res Treat. 2016 Apr;156(2):289-99. doi: 10.1007/s10549-016-3748-5. Epub 2016 Mar 9.
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • iPrevent(®): a tailored, web-based, decision support tool for breast cancer risk assessment and management.
    • Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P, Weideman P, Steel E, Trainer A, Bressel M, Hopper JL, Cuzick J, Antoniou AC, Phillips KA.
    • Breast Cancer Res Treat. 2016 Feb;156(1):171-82. doi: 10.1007/s10549-016-3726-y. Epub 2016 Feb 24.
    • Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation.
    • Howe R, Miron-Shatz T, Hanoch Y, Omer ZB, O'Donoghue C, Ozanne EM.
    • J Genet Couns. 2015 Oct;24(5):744-51. doi: 10.1007/s10897-014-9803-7. Epub 2014 Dec 18.
    • Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.
    • Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO.
    • Genet Med. 2015 Sep 2;17(9):726-32. doi: 10.1038/gim.2014.183. Epub 2014 Dec 11.
    • Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women.
    • Kukafka R, Yi H, Xiao T, Thomas P, Aguirre A, Smalletz C, David R, Crew K.
    • J Med Internet Res. 2015 Jul 14;17(7):e165. doi: 10.2196/jmir.4028.
    • Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers.
    • Özmen V.
    • J Breast Health (2013). 2015 Jul 1;11(3):101-105. doi: 10.5152/tjbh.2015.0001. eCollection 2015.
    • Evolving Information Needs among Colon, Breast, and Prostate Cancer Survivors: Results from a Longitudinal Mixed-Effects Analysis.
    • Tan AS, Nagler RH, Hornik RC, DeMichele A.
    • Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1071-8. doi: 10.1158/1055-9965.EPI-15-0041. Epub 2015 May 15.
    • An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps.
    • Subramanian J, Karmegam A, Papageorgiou E, Papandrianos N, Vasukie A.
    • Comput Methods Programs Biomed. 2015 Mar;118(3):280-97. doi: 10.1016/j.cmpb.2015.01.001. Epub 2015 Jan 21.
    • Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
    • van Driel CM, de Bock GH, Arts HJ, Sie AS, Hollema H, Oosterwijk JC, Mourits MJ.
    • Maturitas. 2015 Mar;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009. Epub 2014 Dec 30.
    • Cancer risk management decision making for BRCA+ women.
    • Leonarczyk TJ, Mawn BE.
    • West J Nurs Res. 2015 Jan;37(1):66-84. doi: 10.1177/0193945913519870. Epub 2014 Jan 26.
    • Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registry.
    • Walker MJ, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA, Chiarelli AM.
    • Breast. 2014 Aug;23(4):482-8. doi: 10.1016/j.breast.2014.04.001. Epub 2014 May 10.
    • Decision Making After BRCA Genetic Testing.
    • Connors LM, Voian N, Shi Y, Lally RM, Edge S.
    • Clin J Oncol Nurs. 2014 Jun 1;18(3):E58-63. doi: 10.1188/14.CJON.E58-E63.
    • The Genetic Testing Experience of BRCA-Positive Women: Deciding Between Surveillance and Surgery.
    • Hesse-Biber S.
    • Qual Health Res. 2014 Jun;24(6):773-789. Epub 2014 Apr 18.
    • Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
    • Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B.
    • J Genet Couns. 2014 Apr;23(2):254-61. doi: 10.1007/s10897-013-9656-5. Epub 2013 Oct 11.
    • In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
    • Hoskins LM, Werner-Lin A, Greene MH.
    • PLoS One. 2014 Feb 28;9(2):e87696. doi: 10.1371/journal.pone.0087696. eCollection 2014.
    • Providing care for previvors: implications for oncology nurses.
    • Mahon SM.
    • Clin J Oncol Nurs. 2014 Feb;18(1):21-4. doi: 10.1188/14.CJON.21-24.
    • Review, Case reports
    • Patient compliance based on genetic medicine: a literature review.
    • Schneider KI, Schmidtke J.
    • J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.
    • Comparison of the Screening Practices of Unaffected Noncarriers under 40 and between 40 and 49 in BRCA1/2 Families.
    • Duprez C, Christophe V, Milhabet I, Krzeminski A, Adenis C, Berthet P, Peyrat JP, Vennin P.
    • J Genet Couns. 2013 Aug;22(4):469-81. doi: 10.1007/s10897-012-9569-8. Epub 2013 Jan 25.
    • Reproductive decision-making in young female carriers of a BRCA mutation.
    • Donnelly LS, Watson M, Moynihan C, Bancroft E, Evans DG, Eeles R, Lavery S, Ormondroyd E.
    • Hum Reprod. 2013 Apr;28(4):1006-12. doi: 10.1093/humrep/des441. Epub 2013 Jan 4.
    • Catalysts to withdrawal from familial ovarian cancer screening for surgery and reactions to discontinued screening: a qualitative study.
    • Lifford KJ, Clements A, Fraser L, Lancastle D, Brain K.
    • Fam Cancer. 2013 Mar;12(1):19-26. doi: 10.1007/s10689-012-9567-x.
    • Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
    • Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.
    • Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.
    • Factors associated with surgical decision making in women with early-stage breast cancer: a literature review.
    • Mac Bride MB, Neal L, Dilaveri CA, Sandhu NP, Hieken TJ, Ghosh K, Wahner-Roedler DL.
    • J Womens Health (Larchmt). 2013 Mar;22(3):236-42. doi: 10.1089/jwh.2012.3969. Epub 2013 Feb 21.
    • Review
    • Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
    • Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M; GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devillee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K.
    • PLoS Genet. 2013 Mar;9(3):e1003173. doi: 10.1371/journal.pgen.1003173. Epub 2013 Mar 27.
    • Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
    • Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA.
    • PLoS Genet. 2013 Mar;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.
    • A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25.
    • Hoskins LM, Werner-Lin A.
    • J Genet Couns. 2013 Feb;22(1):27-38. doi: 10.1007/s10897-012-9521-y. Epub 2012 Aug 3.
    • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    • Korfage IJ, Fuhrel-Forbis A, Ubel PA, Zikmund-Fisher BJ, Greene SM, McClure JB, Smith DM, Alford SH, Fagerlin A.
    • Breast Cancer Res. 2013;15(5):R74.

    Related:

    Comment, Editorial:

    Decision aids for breast cancer chemoprevention.

    • Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm.
    • Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D, Phelps C, Watson EK, Clements A, Menon U.
    • Gynecol Oncol. 2012 Dec;127(3):556-63. doi: 10.1016/j.ygyno.2012.08.034. Epub 2012 Aug 31.
    • 'Cancer doesn't have an age': Genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    • Werner-Lin A, Hoskins LM, Doyle MH, Greene MH.
    • Health (London). 2012 Nov;16(6):636-54. doi: 10.1177/1363459312442420. Epub 2012 Apr 30.
    • Breast cancer genetic counseling after diagnosis but before treatment: A pilot study on treatment consequences and psychological impact.
    • Wevers MR, Hahn DE, Verhoef S, Bolhaar MD, Ausems MG, Aaronson NK, Bleiker EM.
    • Patient Educ Couns. 2012 Oct;89(1):89-95. doi: 10.1016/j.pec.2012.03.019. Epub 2012 Apr 28.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article requests

    • BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis.
    • Julian-Reynier C, Fabre R, Coupier I, Stoppa-Lyonnet D, Lasset C, Caron O, Mouret-Fourme E, Berthet P, Faivre L, Frenay M, Gesta P, Gladieff L, Bouhnik AD, Protière C, Noguès C.
    • Genet Med. 2012 May;14(5):527-34. doi: 10.1038/gim.2011.27. Epub 2012 Jan 12.
    • Disparities in cancer screening in individuals with a family history of breast or colorectal cancer.
    • Ponce NA, Tsui J, Knight SJ, Afable-Munsuz A, Ladabaum U, Hiatt RA, Haas JS.
    • Cancer. 2012 Mar 15;118(6):1656-63. doi: 10.1002/cncr.26480. Epub 2011 Aug 25.

    Related:

    Press: Cancer Screening Lags in Latinos With Family History. (Medscape/Reuters)

    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer.
    • Kwiatkowski F, Dessenne P, Laquet C, Petit MF, Bignon YJ.
    • Eur J Hum Genet. 2012 Feb;20(2):141-7. doi: 10.1038/ejhg.2011.169. Epub 2011 Sep 21.
    • Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic.
    • Brinton JT, Barke LD, Freivogel ME, Jackson S, O'Donnell CI, Glueck DH.
    • Acad Radiol. 2012 Jan;19(1):95-9. doi: 10.1016/j.acra.2011.09.003. Epub 2011 Nov 3.
    • Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS).
    • Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D, Phelps C, Watson EK, Clements A, Iredale R, Jacobs I, Menon U, Brain KE.
    • Gynecol Oncol. 2012 Jan;124(1):158-163. Epub 2011 Oct 15.
    • Worry is good for breast cancer screening: a study of female relatives from the ontario site of the breast cancer family registry.
    • Zhang LR, Chiarelli AM, Glendon G, Mirea L, Knight JA, Andrulis IL, Ritvo P.
    • J Cancer Epidemiol. 2012;2012:545062. doi: 10.1155/2012/545062. Epub 2012 Jun 28.